Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1038920200190030061
Annals of Optometry and Contact Lens
2020 Volume.19 No. 3 p.61 ~ p.66
Safety Evaluation of Bilateral Same-day Intravitreal Ranibizumab Injections
Ahn Ja-Young

Jang Kyu-Hwan
Sohn Joon-Hong
Hwang Duck-Jin
Abstract
Purpose: This study aimed to evaluate the safety of bilateral same-day intravitreal ranibizumab injections by analyzing ophthalmic complications.

Methods: Medical records of patients who underwent bilateral same-day intravitreal ranibizumab injections between January 2016 and December 2018 were retrospectively reviewed. Patient follow-up visits occurred 1 day, 1 month, and 2 months after the injections.

Results: The study included a total of 31 patients, 62 eyes, and 148 bilateral same-day intravitreal ranibizumab injections. The most frequent cause for treatment was exudative age-related macular degeneration, totaling 126 injections (85.1%). Diabetic macular edema accounted for 20 injections (13.5%), and macular edema due to retinal vein occlusion accounted for two injections (1.4%). There were no cases of endophthalmitis, retinal detachment, or vitreous hemorrhage in any patient. We observed five eyes (3.38%) with sterile inflammation, of which three improved without any treatment. The remaining two eyes were in a single patient, and the inflammation improved after four days of treatment. Four eyes (2.7%) exhibited vitreous floaters, and subconjunctival hemorrhage was observed in five eyes (3.38%).

Conclusions: The ocular complication rate of bilateral same-day intravitreal ranibizumab injection procedure was low.
KEYWORD
Bilateral, Endophthalmitis, Intravitreal injection, Ranibizumab, Sterile inflammation
FullTexts / Linksout information
Listed journal information